Glaxo Wellcome has appointed MediTech Media to help recruit more
patients for clinical trials into a new treatment for manic
The international account win follows a three-way pitch between MediTech
Media, Hill and Knowlton and Shire Hall Communications.
Lamotrigine is currently licensed to treat epilepsy, but will not be
approved as a treatment for manic depression until the year 2000.
’Lamotrigine is a mood stabiliser, so it was put into development as a
potential treatment for manic depression,’ said Kate Davies, associate
director at MediTech Media. ’Our programme is to recruit more patients
into the clinical trials.’
Trials are being held in 20 different countries and MediTech Media will
provide guidance and core materials to Glaxo Wellcome operators in
’We will be targeting lay media and medical press to get GPs and
physicians to look at patients who might be suitable,’ said Davies.
MediTech Media plans to use creative figures who suffered from manic
depression, such as Vincent van Gogh, Byron and Virginia Woolf, to
attract media attention.
’There can be a fine line between creative genius and psychiatric
illness,’ said Davies.
MediTech Media also works for Glaxo Wellcome supporting products for
epilepsy, herpes, HIV and Aids.